{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:10:27Z","timestamp":1792789827606,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005620","name":"North Carolina GlaxoSmithKline Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011699","name":"Siemens Healthineers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.eururo.2019.12.017","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T03:32:31Z","timestamp":1578367951000},"page":"675-682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":239,"title":["Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort"],"prefix":"10.1016","volume":"77","author":[{"given":"Jeffrey J.","family":"Tosoian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mufaddal","family":"Mamawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Landis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna J.","family":"Macura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrios N.","family":"Simopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Ballentine","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Gorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2019.12.017_bib0005","series-title":"NCCN clinical practice guidelines in oncology: prostate cancer","author":"Mohler","year":"2019"},{"key":"10.1016\/j.eururo.2019.12.017_bib0010","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.eururo.2018.06.008","article-title":"Active surveillance for low-risk prostate cancer: the European Association of Urology Position in 2018","volume":"74","author":"Briganti","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0015","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0020","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1200\/JCO.2015.62.5764","article-title":"Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer","volume":"33","author":"Tosoian","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0025","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.juro.2014.09.094","article-title":"Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer","volume":"193","author":"Welty","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0030","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.eururo.2016.03.048","article-title":"Long-term results of active surveillance in the G\u00f6teborg randomized, population-based prostate cancer screening trial","volume":"70","author":"Godtman","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0035","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.eururo.2016.06.007","article-title":"A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment","volume":"70","author":"Bokhorst","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0040","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1200\/JCO.18.00606","article-title":"Clinically localized prostate cancer: ASCO clinical practice guideline endorsement of an American Urological Association\/American Society for Radiation Oncology\/Society of Urologic Oncology guideline","volume":"36","author":"Bekelman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0045","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.eururo.2013.05.049","article-title":"Systematic review of complications of prostate biopsy","volume":"64","author":"Loeb","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0050","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0022-5347(05)65271-8","article-title":"Expectant management of nonpalpable prostate cancer with curative intent: preliminary results","volume":"167","author":"Carter","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0055","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/jama.1994.03510290050036","article-title":"Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1 c) prostate cancer","volume":"271","author":"Epstein","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2019.12.017_bib0060","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.1464-410X.2012.11641.x","article-title":"Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance","volume":"111","author":"Mullins","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.12.017_bib0065","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","article-title":"PI-RADS Prostate Imaging \u2013 Reporting and Data System: 2015, version 2","volume":"69","author":"Weinreb","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0070","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.eururo.2016.05.021","article-title":"The role of multiparametric magnetic resonance imaging\/ultrasound fusion biopsy in active surveillance","volume":"71","author":"Ma","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0075","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.eururo.2019.12.017_bib0080","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.eururo.2019.12.017_bib0085","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1200\/JCO.2013.50.3540","article-title":"Diagnostic challenges of clonal heterogeneity in prostate cancer","volume":"33","author":"Haffner","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0090","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2018.06.025","article-title":"Active Surveillance Magnetic Resonance Imaging Study (ASIST): results of a randomized multicenter prospective trial","volume":"75","author":"Klotz","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0095","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.juro.2018.08.023","article-title":"Older age predicts biopsy and radical prostatectomy grade reclassification to aggressive prostate cancer in men on active surveillance","volume":"201","author":"Druskin","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0100","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2016.68.0058","article-title":"Active surveillance in younger men with prostate cancer","volume":"35","author":"Leapman","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0105","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.juro.2010.01.015","article-title":"Evidence supports a faster growth rate and\/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity","volume":"183","author":"Powell","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0110","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.urology.2014.05.009","article-title":"Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups","volume":"84","author":"Mahal","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2019.12.017_bib0115","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2012.47.0302","article-title":"African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?","volume":"31","author":"Sundi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0120","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.juro.2016.06.086","article-title":"Pathological and biochemical outcomes among African-American and Caucasian men with low risk prostate cancer in the SEARCH database: implications for active surveillance candidacy","volume":"196","author":"Leapman","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0125","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.juro.2011.12.082","article-title":"Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance","volume":"187","author":"Iremashvili","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0130","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2019.12.017_bib0135","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.juro.2016.06.102","article-title":"Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience","volume":"196","author":"Musunuru","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0140","doi-asserted-by":"crossref","first-page":"228","DOI":"10.21037\/tau.2017.08.13","article-title":"Imaging for the selection and monitoring of men on active surveillance for prostate cancer","volume":"7","author":"Velasquez","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0145","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1200\/JCO.2010.33.0134","article-title":"Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance","volume":"29","author":"Porten","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.12.017_bib0150","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jama.280.11.975","article-title":"Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer","volume":"280","author":"Albertsen","year":"1998","journal-title":"J Am Med Assoc"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283819309613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283819309613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:06:06Z","timestamp":1759583166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283819309613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0302283819309613"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2019.12.017","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2019.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}